<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051566</url>
  </required_header>
  <id_info>
    <org_study_id>17783</org_study_id>
    <secondary_id>J2A-MC-GZGD</secondary_id>
    <secondary_id>QSC202755</secondary_id>
    <secondary_id>2020-005750-15</secondary_id>
    <nct_id>NCT05051566</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of LY3502970 in Healthy Participants</brief_title>
  <official_title>A Multiple Dose Study in Healthy Participants to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3502970</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and&#xD;
      how long it takes the body to remove it when administered in multiple oral doses as new&#xD;
      formulation compared to that of reference LY3502970 formulation. Information about safety and&#xD;
      tolerability will be collected. The study is open to healthy participants. The study is&#xD;
      conducted in two parts and it will last up to about 6 months, inclusive of screening period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">March 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: Cmax of LY3502970</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve (AUC) of LY3502970</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: AUC of LY3502970</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time of Maximum Observed Concentration (Tmax) of LY3502970</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>PK: Tmax of LY3502970</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3502970 Prototype (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 prototype administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Reference (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 reference administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Prototype (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 prototype administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3502970 Reference (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LY3502970 reference administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole (Part B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple doses of Esomeprazole (Proton Pump Inhibitor) administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3502970</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3502970 Prototype (Part A)</arm_group_label>
    <arm_group_label>LY3502970 Prototype (Part B)</arm_group_label>
    <arm_group_label>LY3502970 Reference (Part A)</arm_group_label>
    <arm_group_label>LY3502970 Reference (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Esomeprazole (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined by medical evaluation.&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 35 kilograms per meter squared (kg/mÂ²).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have an abnormal blood pressure and/or pulse rate as determined by the investigator&#xD;
             -minor deviations acceptable to investigator are allowed&#xD;
&#xD;
          -  Have known liver disease, obvious clinical signs or symptoms of liver disease, acute&#xD;
             or chronic hepatitis, or have elevations in aminotransferases (alanine&#xD;
             aminotransferase [ALT] and aspartate aminotransferase [AST]) greater than 2X ULN&#xD;
             (Upper Limit of Normal)&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG at screening that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study&#xD;
&#xD;
          -  Are women of child-bearing potential&#xD;
&#xD;
          -  Are women who are lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Clinical Ltd</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441159749000</phone>
    </contact>
    <investigator>
      <last_name>Som Menakuru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 1, 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

